Gideon Loevinsohn1,2, Godfrey Kigozi3, Joseph Kagaayi3, Maria J Wawer1,3,4, Fred Nalugoda3, Larry W Chang1,3,5, Thomas C Quinn1,5,6, David Serwadda3,7, Steven J Reynolds1,3,5,6, Lisa Nelson8, Lisa Mills8, Stella Alamo8, Gertrude Nakigozi3, Geoffrey Kabuye8, Robert Ssekubugu3, Aaron A R Tobian1,3,9, Ronald H Gray1,3, M Kathryn Grabowski1,3,9. 1. Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA. 2. Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 3. Rakai Health Sciences Program, Kalisizo, Uganda. 4. Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA. 5. Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 6. Laboratory of Immunoregulation, Division of Intramural Research, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. 7. School of Public Health, Makerere University, Kampala, Uganda. 8. US Centers for Disease Control and Prevention Uganda, Kampala, Uganda. 9. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
BACKGROUND: The efficacy of voluntary male medical circumcision (VMMC) for human immunodeficiency virus (HIV) prevention in men was demonstrated in 3 randomized trials. This led to the adoption of VMMC as an integral component of the United States President's Emergency Plan for AIDS Relief (PEPFAR) combination HIV prevention program in sub-Saharan Africa. However, evidence on the individual-level effectiveness of VMMC programs in real-world, programmatic settings is limited. METHODS: A cohort of initially uncircumcised, non-Muslim, HIV-uninfected men in the Rakai Community Cohort Study in Uganda was followed between 2009 and 2016 during VMMC scale-up. Self-reported VMMC status was collected and HIV tests performed at surveys conducted every 18 months. Multivariable Poisson regression was used to estimate the incidence rate ratio (IRR) of HIV acquisition in newly circumcised vs uncircumcised men. RESULTS: A total of 3916 non-Muslim men were followed for 17 088 person-years (PY). There were 1338 newly reported VMMCs (9.8/100 PY). Over the study period, the median age of men adopting VMMC declined from 28 years (interquartile range [IQR], 21-35 years) to 22 years (IQR, 18-29 years) (P for trend < .001). HIV incidence was 0.40/100 PY (20/4992.8 PY) among newly circumcised men and 0.98/100 PY (118/12 095.1 PY) among uncircumcised men with an adjusted IRR of 0.47 (95% confidence interval, .28-.78). The effectiveness of VMMC was sustained with increasing time from surgery and was similar across age groups and calendar time. CONCLUSIONS: VMMC programs are highly effective in preventing HIV acquisition in men. The observed effectiveness is consistent with efficacy in clinical trials and supports current recommendations that VMMC is a key component of programs to reduce HIV incidence.
BACKGROUND: The efficacy of voluntary male medical circumcision (VMMC) for human immunodeficiency virus (HIV) prevention in men was demonstrated in 3 randomized trials. This led to the adoption of VMMC as an integral component of the United States President's Emergency Plan for AIDS Relief (PEPFAR) combination HIV prevention program in sub-Saharan Africa. However, evidence on the individual-level effectiveness of VMMC programs in real-world, programmatic settings is limited. METHODS: A cohort of initially uncircumcised, non-Muslim, HIV-uninfected men in the Rakai Community Cohort Study in Uganda was followed between 2009 and 2016 during VMMC scale-up. Self-reported VMMC status was collected and HIV tests performed at surveys conducted every 18 months. Multivariable Poisson regression was used to estimate the incidence rate ratio (IRR) of HIV acquisition in newly circumcised vs uncircumcised men. RESULTS: A total of 3916 non-Muslim men were followed for 17 088 person-years (PY). There were 1338 newly reported VMMCs (9.8/100 PY). Over the study period, the median age of men adopting VMMC declined from 28 years (interquartile range [IQR], 21-35 years) to 22 years (IQR, 18-29 years) (P for trend < .001). HIV incidence was 0.40/100 PY (20/4992.8 PY) among newly circumcised men and 0.98/100 PY (118/12 095.1 PY) among uncircumcised men with an adjusted IRR of 0.47 (95% confidence interval, .28-.78). The effectiveness of VMMC was sustained with increasing time from surgery and was similar across age groups and calendar time. CONCLUSIONS: VMMC programs are highly effective in preventing HIV acquisition in men. The observed effectiveness is consistent with efficacy in clinical trials and supports current recommendations that VMMC is a key component of programs to reduce HIV incidence.
Authors: Martien W Borgdorff; Daniel Kwaro; David Obor; George Otieno; Viviane Kamire; Frederick Odongo; Patrick Owuor; Jacques Muthusi; Lisa A Mills; Rachael Joseph; Mary E Schmitz; Peter W Young; Emily Zielinski-Gutierrez; Kevin M De Cock Journal: Lancet HIV Date: 2018-04-09 Impact factor: 12.767
Authors: R H Gray; N Kiwanuka; T C Quinn; N K Sewankambo; D Serwadda; F W Mangen; T Lutalo; F Nalugoda; R Kelly; M Meehan; M Z Chen; C Li; M J Wawer Journal: AIDS Date: 2000-10-20 Impact factor: 4.177
Authors: Aaron A R Tobian; David Serwadda; Thomas C Quinn; Godfrey Kigozi; Patti E Gravitt; Oliver Laeyendecker; Blake Charvat; Victor Ssempijja; Melissa Riedesel; Amy E Oliver; Rebecca G Nowak; Lawrence H Moulton; Michael Z Chen; Steven J Reynolds; Maria J Wawer; Ronald H Gray Journal: N Engl J Med Date: 2009-03-26 Impact factor: 91.245
Authors: Joseph Makhema; Kathleen E Wirth; Molly Pretorius Holme; Tendani Gaolathe; Mompati Mmalane; Etienne Kadima; Unoda Chakalisa; Kara Bennett; Jean Leidner; Kutlo Manyake; Atang M Mbikiwa; Selebaleng V Simon; Rona Letlhogile; Kutlwano Mukokomani; Erik van Widenfelt; Sikhulile Moyo; Refeletswe Lebelonyane; Mary G Alwano; Kathleen M Powis; Scott L Dryden-Peterson; Coulson Kgathi; Vlad Novitsky; Janet Moore; Pamela Bachanas; William Abrams; Lisa Block; Shenaaz El-Halabi; Tafireyi Marukutira; Lisa A Mills; Connie Sexton; Elliot Raizes; Simani Gaseitsiwe; Hermann Bussmann; Lillian Okui; Oaitse John; Roger L Shapiro; Sherri Pals; Haben Michael; Michelle Roland; Victor DeGruttola; Quanhong Lei; Rui Wang; Eric Tchetgen Tchetgen; M Essex; Shahin Lockman Journal: N Engl J Med Date: 2019-07-18 Impact factor: 176.079
Authors: Alain Vandormael; Adam Akullian; Mark Siedner; Tulio de Oliveira; Till Bärnighausen; Frank Tanser Journal: Nat Commun Date: 2019-12-02 Impact factor: 14.919